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The central nervous system architecture is markedly modified by sensory experience during early life, but a decline of plasticity
occurs with age. Recent studies have challenged this dogma providing evidence that both pharmacological treatments and
paradigms based on the manipulation of environmental stimulation levels can be successfully employed as strategies for enhancing
plasticity in the adult nervous system. Insulin-like growth factor 1 (IGF-1) is a peptide implicated in prenatal and postnatal phases
of brain development such as neurogenesis, neuronal diﬀerentiation, synaptogenesis, and experience-dependent plasticity. Here,
using the visual system as a paradigmatic model, we report that IGF-1 reactivates neural plasticity in the adult brain. Exogenous
administration of IGF-1 in the adult visual cortex, indeed, restores the susceptibility of cortical neurons to monocular deprivation
and promotes the recovery of normal visual functions in adult amblyopic animals. These eﬀects were accompanied by a marked
reduction of intracortical GABA levels. Moreover, we show that a transitory increase of IGF-1 expression is associated to the
plasticity reinstatement induced by environmental enrichment (EE) and that blocking IGF-1 action bymeans of the IGF-1 receptor
antagonist JB1 prevents EE eﬀects on plasticity processes.
1. Introduction
The brain processes information from the external world
and creates neuronal representations of the environment that
change in response to sensory experience [1]. The extent
to which environmental stimuli modify brain structure and
function has been extensively studied in the visual system.
Visual cortical circuitries are highly sensitive to experience
during well-defined temporal windows in early life, known as
critical periods (CPs), but this phase of heightened plasticity
decreases over postnatal development [2, 3]. Pioneering
electrophysiological studies demonstrated that occluding
one eye early in development (monocular deprivation, MD)
leads to an ocular dominance (OD) shift of cortical neurons,
that is, a reduction in the number of cortical cells responding
to that eye and an increment of neurons driven by the open
eye [4, 5]. In addition, the deprived eye becomes amblyopic:
its acuity and contrast sensitivity are dramatically reduced.
Because MD does not trigger amblyopia in adulthood, this
early temporal window characterized by enhanced plasticity
in response to experience is a typical example of a CP.
Converging evidence attributes the decline of plasticity
that occurs with age to the maturation of intracortical
inhibitory circuitries [6–8]. A direct demonstration that
GABAergic inhibition is a crucial brake limiting plasticity in
the adult visual cortex (VC) derives from a study showing
that the pharmacological reduction of intracortical inhibi-
tion reactivates OD plasticity in adult life [9]. Accordingly,
diﬀerent experimental approaches that shift the cortical
inhibitory/excitatory balance have been reported to trigger
the reinstatement of neural plasticity in the adult brain
[10–15].
2 Neural Plasticity
Environmental enrichment (EE) is an experimental
paradigm characterized by enhanced sensory-motor and
cognitive stimulation that has a profound impact on brain
structure and function [16, 17]. It has been recently demon-
strated that short periods of EE in adulthood reactivate
juvenile-like plasticity in the visual system, promoting both
a marked OD shift of cortical neurons in response to MD
and the recovery of normal visual functions after long-
term sensory deprivation [12, 18, 19], reviewed in [17, 20].
This has prompted the search for endogenous factors with
the potential to enhance experience-dependent plasticity
(enviromimetics) as a therapeutic strategy for brain repair in
adult life.
A candidate molecule that might be exploited to repro-
duce the beneficial eﬀects of EE is insulin-like growth factor 1
(IGF-1). IGF-1 is a peptide implicated in early phases of brain
development, and there is evidence that IGF-1 underlies
the eﬀects caused by physical activity in synaptic plasticity
and hippocampal neurogenesis [21–24]. It has been reported
that MD during the CP increases the expression of IGF-
1 binding proteins and aﬀects diﬀerent genes of the IGF-
1 pathway [25]. In addition, exogenous administration of
IGF-1 prevents the physiological eﬀect of MD during the CP
[25]. Developmental studies using EE as a strategy to assess
environmental influences on brain function further con-
firm the role of IGF-1 in mediating experience-dependent
plasticity. In rodents, EE increases IGF-1 cortical levels
and accelerates development of normal visual functions,
whereas blocking IGF-1 signaling in EE animals prevents
this plastic phenomenon [26, 27]. In humans, enriching
the environment in terms of body massage accelerates the
developmental maturation of visual functions and, as in
the oﬀspring of rats, this phenomenon is accompanied by
enhanced IGF-1 levels [28].
Despite these findings, a thorough analysis of IGF-1
eﬀects on adult visual cortical plasticity is still missing. Here,
we addressed this issue by using two classical paradigms
of experience-dependent plasticity: (i) the shift of OD in
response to MD and (ii) the recovery of visual functions
in adult amblyopic animals. In the rat, these two plastic
events are restricted to the CP during early stages of devel-
opment. We report that intracortical IGF-1 administration
reactivates neural plasticity in the adult VC. These eﬀects
were accompanied by a marked reduction of intracortical
GABA levels. Moreover, we show that a transitory increase of
IGF-1 expression accompanies the reinstatement of plasticity
caused by EE in adulthood and that blocking IGF-1 action
by means of the IGF-1 receptor antagonist JB1 prevents EE
eﬀects on plasticity processes.
2. Methods
2.1. Subjects. A total of 92 adult Long-Evans hooded rats at
the postnatal day 70 (P70) were used in this study, which was
approved by the Italian Ministry of Public Health. Animals
were group-housed under standard conditions with food and
water ad libitum in Plexiglas cages (40×30×20 cm) and kept
in a 12 : 12 light/dark cycle.
2.2. Surgical Treatments. To assess OD plasticity, MD was
performed by eyelid suturing. Animals were anesthetized
with avertin (1mLhg−1), mounted on a stereotaxic appara-
tus, and eyelid closure performed by sewing of the eyelids
using sterile-surgical sutures. Eyelid closure was inspected
daily until complete cicatrization, and subjects with even
minimal spontaneous reopening were excluded. Great care
was taken to prevent inflammation or infection in the
deprived eye through topical application of antibiotic and
cortisone.
To assess amblyopia recovery, young animals (P21)
were anesthetized with avertin (1mL hg−1) and monocularly
deprived by eyelid suture. Eyelid occlusion was inspected
daily until complete cicatrization; subjects with even mini-
mal spontaneous re-opening were excluded. Adult long-term
deprived (amblyopic) rats were then subjected to reverse
suture (RS) in parallel to the intracortical infusion of IGF-1
or vehicle solution; that is, the long-term deprived eye was
opened while the other eye was sutured shut during two
weeks. Great care was taken during the first days after RS to
prevent inflammation or infection in the previously deprived
eye through topical application of antibiotic and cortisone.
2.3. Intracortical Administration of IGF-1 and JB1. Adult
rats (P70) were anesthetized with avertin (1mL hg−1) and
osmotic minipumps, connected via PE tubing to a stainless
steel cannula (30 gauge), implanted in the VC for 2 weeks.
Osmotic minipumps (14-day flow rate: 0.5 μL hr−1) were
filled up with IGF-1 (0.5 μg μL−1), the IGF-1 receptor
antagonist JB1 (10 μgmL−1), or vehicle solution (saline) and
implanted 4.5mm lateral and 2mm anterior to λ (i.e., 2mm
distant from the site of electrophysiological recordings) in
the VC contralateral to the deprived eye, as previously
described [12, 15]. This treatment caused no damage in
the binocular region of the VC where electrophysiological
recordings were performed.
2.4. In Vivo Electrophysiology. After respective treatments,
adult rats (P85–90) were anesthetized with urethane (0.7mL
hg−1; 20% solution in saline) by i.p. injection and placed
in a stereotaxic frame. Additional doses of urethane were
used to keep the anesthesia level stable throughout the
experiment. Body temperature was continuously monitored
and maintained at ∼37◦C by a thermostated electric blanket
during the experiment. An ECG was continuously moni-
tored. A hole was drilled in the skull, corresponding to the
binocular portion of the primary VC (Oc1B) contralateral
to the deprived eye. After exposure of the brain surface, the
dura was removed, and a micropipette (2MΩ) filled with
NaCl (3M) was inserted into the cortex 5mm lateral and
0mm anterior to λ (i.e., 2mm distant from the injection
site in which no damage of the cortex was observed). Both
eyes were fixed and kept open by means of adjustable
metal rings surrounding the external portion of the eye
bulb. Alterations of binocularity and visual acuity (VA)
were measured by using visual evoked potentials (VEPs).
To record VEPs, the electrode was advanced at a depth of
100 or 400 μm within the cortex. At these depths, VEPs
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Table 1: Detailed description of the oligos (sense/antisense) used to amplify genes of interest.
Gene Oligo sense Oligo antisense
IGF-1 CAGTTCGTGTGTGGACCAAG CAACACTCATCCACAATGCC
IGF1-R TGAACCCCGAGTATTTCAGC GGCCACTCCTTCATAGACCA
IGFbp5 GGTTTGCCTCAACGAAAAGA GAAGACCTTCGGGGAGTAGG
IGFbp3 GCTATGACACCAAGGGGAA TTGTTGGCAGTCTTTTGTGC
had their maximal amplitude [29]. Signals were band-pass-
filtered (0.1–100Hz), amplified, and fed to a computer
for analysis, as described previously [7]. Briefly, at least
128 events were averaged in synchrony with the stimulus
contrast reversal. Transient VEPs in response to abrupt
contrast reversal (0.5Hz) were evaluated in the time domain
by measuring the peak-to-baseline amplitude and peak
latency of the major negative component. Visual stimuli were
horizontal sinusoidal gratings of diﬀerent spatial frequencies
and contrast, generated by a VSG2/2 card running custom
software and presented on amonitor (20× 22 cm; luminance
15 cd m−2) positioned 20 cm from the rat’s eyes and centered
on the previously determined receptive fields. VA was
obtained by extrapolation to zero amplitude of the linear
regression through the last four to five data points in a
curve where VEP amplitude is plotted against log spatial
frequency. Binocularity (OD) was assessed calculating the
contralateral to ipsilateral (C/I) VEP ratio, that is, the ratio of
VEP amplitudes recorded by stimulating the eye, respectively,
contralateral and ipsilateral to the VC where recording is
performed. To prevent sampling bias, VEPs were recorded
at three diﬀerent penetrations in Oc1b and at 100 μm and
400 μm depths for each penetration.
2.5. In Vivo Brain Microdialysis. To perform brainmicrodial-
ysis, adult rats (P85–90) were anesthetized and stereotaxi-
cally implanted with stainless steel guide shafts above Oc1B
at coordinates: 7.3mmposterior to bregma, 4.4mm lateral to
the midsagittal suture, and 1mm ventral to the skull, as pre-
viously described [11, 12]. One week later, in vivo sampling
of dialysates was performed inserting a microdialysis probe
into the guide shaft previously implanted. The probe was
made of concentric fused-silica polyimide-covered capillary
tube into a 26-gauge stainless steel tube with a 1mm long
tip of exposed cellulose membrane (6000MW cutoﬀ). It was
connected to a dialysis system pumping an artificial CSF
(142mM NaCl, 3.9mM KCl, 1.2mM CaCl2, 1mM MgCl2,
1.35mM Na2HPO4, pH 7.4) at a flow rate of 1 μL min−1.
The probe protruded 1mm from the tip of the guide shaft.
Six hours after insertion of the probe (stabilization period),
sampling was carried out. Six samples (20 μL each) were
collected every 20min along 2 hours for each freely moving
animal.
2.6. High-Performance Liquid Chromatography. Analysis of
γ-aminobutyric acid (GABA) and glutamate (GLU) basal
levels from microdialysates was performed using high
performance liquid chromatography (HPLC) coupled to a
fluorimetric detection system. A sample automatic deriva-
tization (Waters 2690 Alliance) with o-phthalaldehyde was
followed [11, 12, 19]. Resolution was obtained through a
C18 reverse-phase chromatographic column coupled to the
fluorometric detection (Waters 474; excitation wavelength
350 nm, emission wavelength recorder 450 nm). Buﬀer and
gradient program was as follows: by definition, solvent A:
0.1M sodium acetate pH 5.8/methanol 20/80; solvent B:
0.1M sodium acetate pH 5.8/methanol 80/20; solvent C:
0.1M sodium acetate pH 6.0/methanol 80/20. Concerning
the gradient program, initial isocratic step 5% A, 95%C
from 0 to 5min; 15% A, 85% B from 4 to 5min and then
isocratic until 9min; 22% A, 66% B until 14.5min and then
34% A, 66% B until 17min; 5% A, 95% C until 19min
and then isocratic until 23min. Flow rate was 0.9mLmin−1.
Homoserine was used as internal standard, and amino acid
concentrations were calculated from a linear standard curve
built upon known concentrations of injected amino acids.
Area of the peaks was used to make comparisons (Waters
Millenium 32).
2.7. Rearing Environments. Enriched environment consisted
of a large cage (100 × 50 × 82 cm) with a wire mesh
lid containing several food hoppers, a running wheel, and
diﬀerently shaped objects (tunnels, shelters, stairs) that were
repositioned once per day and completely substituted with
others once per week, as described previously [12, 19]. Every
enriched cage housed at least six rats. Standard conditions
consisted of standard laboratory cages (40 × 30 × 20 cm)
housing each 2 rats. Litter and food were the same in
both experimental conditions; food and water provided
at libitum.
2.8. Real-Time PCR. After respective treatments, Oc1b was
dissected and immediately frozen. RNA purification was
performed according to the standard Trizol procedure (Invit-
rogen). Purified RNA was treated with DNAse (Fermentas),
and cDNA was synthesized from 1 ug of RNA (Invitro-
gen). Real-time PCR was carried out to determine relative
enrichment in the samples using the SYBER Green method
according to the manufacturer instructions (SYBR Green
I master, Light cycler 480, Roche Diagnostics). The com-
parative Ct method was used to determine the normalized
changes of the target gene relative to a calibrator reference,
as described previously [15]. mRNA quantification samples
were normalized to GAPDH levels. As calibrator reference
we referred to Ct from control animal samples. Gene
expression patterns of interest (see Table 1) were analyzed
at two diﬀerent time points during EE: after 2 and 7 days,
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respectively, during the last week of EE. Respective control
animals housed under standard conditions were similarly
treated.
3. Results
To address the functional relevance of IGF-1 signaling in
the process of plasticity reactivation, we initially evaluated
OD plasticity in adult rats that were infused in the VC with
IGF-1 (0.5 μg μL−1), via osmotic minipumps, during 2 weeks
and monocularly deprived during the last week of treatment.
Plasticity was assessed by electrophysiological recordings of
VEPs in the binocular region of the primary VC contralateral
to the deprived eye (see methods). We measured the
contralateral-to-ipsilateral (C/I) VEP ratio, which is the
ratio of VEPs amplitudes recorded by stimulating the eye
contralateral and ipsilateral, respectively, to the VC where
recording is performed [29]. The C/I ratio was in the range
of 2-3 in adult animals with binocular vision (C/I VEP ratio
2.42 ± 0.16; n = 5), reflecting the predominance of crossed
fibers in the rat retinal projections. As shown in Figure 1(a),
a significant shift of OD after MD was observed in IGF-1
treated rats (IGF-1+MD; C/I VEP ratio = 1.2 ± 0.17; n = 5,
One-way ANOVA, F(4–21) = 8.838, P = 0.0002, post hoc
Tukey’s test, P < 0.05) but not in rats infused with vehicle
solution (SAL+MD; C/I VEP ratio = 2.67 ± 0.15, n = 5)
or normal animals (Nor+MD; C/I VEP ratio = 2.53 ± 0.25;
n = 7). No modification of OD was observed in control IGF-
1 infused rats with binocular vision, indicating that IGF-1
treatment per se does not alter OD properties of VC neurons
(IGF-1+Bin; C/I VEP ratio = 2.37 ± 0.14, n = 3).
To examine whether the OD shift observed in IGF-
1+MD animals was due to a weakening of the deprived
eye strength or to a strengthening of open eye responses
[30, 31], we compared VEP amplitudes in response to the
stimulation of each eye in IGF1- and saline-treated animals
after MD. We report that the amplitude of VEPs recorded in
response to stimulation of the occluded eye in IGF-1+MD
rats (VEP amplitude 0.35 ± 0.05) was significantly lower
(t-test; P = 0.047,n = 5) with respect to that obtained
in saline-treated animals (VEP amplitude = 0.68 ± 0.12)
after MD (Figure 1(a), Insert). No diﬀerence was detected in
VEP amplitudes recorded after stimulation of the open eye
(IGF-1+MD: VEP amplitude = 0.38 ± 0.11; SAL+MD: VEP
amplitude = 0.32 ± 0.05).
We next assessed whether the potential for the reac-
tivation of plasticity caused by IGF-1 treatment could be
employed to promote the recovery of sensory functions from
long-term deprivation using amblyopia as a paradigmatic
model. Animals that were rendered amblyopic by long-term
sensory deprivation were intracortically treated in adulthood
with IGF-1 or vehicle solution, in parallel to reverse suture
(RS), during two weeks (see methods). Visual acuity (VA)
was measured by recordings of VEPs in the VC contralateral
to the long-term deprived eye. Figure 1(b) shows that VA of
the long-term deprived eye (0.67 ± 0.01 cycles per degree,
c/deg) was significantly lower (paired t-test; P = 0.0016,n =
5) than that of the fellow eye (0.97± 0.02 c/deg) in amblyopic
animals after RS (Nor+RS). In contrast, a full rescue of VA
was observed in reverse-sutured IGF-1 treated rats (IGF-
1+RS; VA for the long-term deprived eye = 0.93± 0.06 c/deg;
VA for the open eye 0.94 ± 0.04 c/deg; paired t-test; P =
0.229,n = 5). No sign of recovery was detected in control
amblyopic animals infused with vehicle solution after RS
(SAL+RS).
We also evaluated OD recovery by measuring the C/I
VEP ratio in the same rats in which we measured VA (Figure
1(b), Insert). No recovery of binocularity was observed in
adult amblyopic rats after RS (Nor+RS; C/I VEP ratio =
1.02 ± 0.08;n = 5). In contrast, the OD of visual cortical
neurons was dominated by the contralateral eye in IGF1-
treated animals (IGF-1+RS), showing a mean VEP ratio in
the range of normal adult values and predictive of a full
recovery of binocularity (C/I VEP ratio = 2.12± 0.13;n = 5,
One-way ANOVA, F(3–16) = 40.24, P < 0.0001, post hoc
Tukey’s test, P < 0.05). No rescue of OD was detected
in control vehicle-treated rats (SAL+RS; C/I VEP ratio =
0.86± 0.11).
Because there is evidence that a reduction of local
inhibitory transmission underlies the reinstatement of plas-
ticity in the adult visual system [9–12, 19], we investigated
whether the IGF-1-mediated reactivation of plasticity was
accompanied by a reduction of local GABAergic inhibition.
In vivo brain microdialysis revealed that extracellular basal
levels of GABA were markedly reduced (Figure 1(c); One-
way ANOVA, F(2–16) = 7.445, P = 0.0052, post hoc Tukey’s
test, P < 0.05) in the VC of IGF-1 treated rats (0.87±0.2μM;
n = 6) as compared to both normal rats (4.62 ± 0.97μM;
n = 8) and vehicle-treated counterparts (4.46 ± 0.5μM;
n = 5). No significant diﬀerence in basal glutamate (GLU)
levels between any of the experimental groups was detected
(Figure 1(d)).
Since it has been demonstrated that IGF-1 is a crucial
molecule underlying EE eﬀects on visual system develop-
ment [27], we next addressed whether IGF-1 mediates the
EE-induced reactivation of plasticity in the adult VC. We
used real-time PCR to investigate the expression of IGF-1
pathway genes in the VC of adult rats that were exposed
to EE during 2 weeks. We assessed gene expression in two
diﬀerent groups of adult animals that were monocularly
deprived for either 2 or 7 days, respectively, during the last
week of EE (see methods). Interestingly, expression of IGF-1
significantly increased (t-test; P = 0.034, n = 8) after 2 but
not 7 days of MD in the VC of EE animals as compared to
respective controls (Figures 2(a) and 2(b)). No change in the
expression of the IGF-1 receptor was observed. Expression of
the IGF-1 binding protein 5 (IGFbp5) increased after 2 days
of MD (t-test; P = 0.030,n = 8), whereas no modification of
IGFbp3 expression was evidenced in any of the experimental
groups (Figures 2(a) and 2(b)).
We next examined whether IGF-1 is causally linked to the
EE-induced process of plasticity reactivation. Adult rats were
intracortically infused with the IGF-1 receptor antagonist
JB1 (10 μgmL−1) in parallel to the period of EE. This
treatment has been previously used to assess development of
normal visual functions in rodents [27]. The C/I VEP ratio
shifted in response toMD (One-way ANOVA, F(5–27) = 46.48,
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Figure 1: IGF-1 treatment reactivates plasticity in the adult visual cortex and decreases intracortical GABA levels. (a) An OD shift in favor of
the open eye was evident in IGF-1-infused rats (IGF-1+MD; n = 5, C/I VEP ratio = 1.2 ± 0.17) with respect to adult animals with binocular
vision (Nor+Bin; n = 5, C/I VEP ratio = 2.42± 0.16, one-way ANOVA P = 0.0002, post hoc Holm Sidakmethod, P < 0.05). Nomodification
of the C/I VEP ratio was detected in either saline-treated animals (SAL+MD; n = 5, C/I VEP ratio = 2.67 ± 0.15, One-way ANOVA, post
hoc Holm Sidak method) or normal adult rats (Nor+MD; n = 7, C/I VEP ratio = 2.53 ± 0.25, One-way ANOVA, post hoc Holm Sidak
method). IGF-1 treated rats with binocular vision (IGF-1+Bin; n = 3) exhibited a C/I VEP ratio (2.37 ± 0.12) completely comparable to
that of untreated Nor+Bin animals (One-way ANOVA, post hoc Holm Sidak method). Insert: the change of OD in IGF-1-treated rats was
due to a decrease of the deprived eye (contra) strength. The amplitude of VEPs recorded in response to the stimulation of the occluded
eye in IGF-1+MD rats (0.35 ± 0.05) was significantly lower with respect to that obtained in saline-treated animals following MD (0.68 ±
0.12; t-test; P = 0.047). No diﬀerence was detected in VEP amplitudes recorded after the stimulation of the open (Ipsi) eye (IGF-1+MD:
0.38 ± 0.11; SAL+MD: 0.32 ± 0.05; t-test; P = 0.627). VEP amplitudes at the recording site in the VC contralateral to the occlusion were
normalized to the sum of the response to stimulation of the contralateral and ipsilateral eye, as described previously [10–12]. (b) Full rescue
of VA was evident in reverse-sutured IGF-1 treated rats (IGF-1+RS, n = 5): VA of the long-term deprived eye (0.93 ± 0.06 cycles per degree,
c/deg) was not diﬀerent from that of the fellow eye (0.94 ± 0.04 c/deg; paired t-test, P = 0.837). No sign of recovery was detected either in
reverse-sutured animals infused with saline (SAL+RS, n = 5; VA for the long-term deprived eye = 0.72±0.03 c/deg; VA for the open eye 0.96
± 0.01 c/deg; paired t-test, P < 0.001) or in reverse-sutured normal rats (Nor+RS, n = 5; VA for the long-term deprived eye = 0.67 ± 0.01
c/deg; VA for the open eye 1.03 ± 0.03 c/deg; paired t-test; P < 0.001) Insert, while in Nor-RS rats (C/I VEP ratio = 1.02 ± 0.08) there was no
recovery of binocularity (One-way ANOVA, post hoc Holm Sidak method); in IGF1+RS the C/I VEP ratio is in the range of normal adult
values (C/I VEP ratio 2.12 ± 0.13, One-way ANOVA, F(3-16) = 40.24, P < 0.0001, post hoc Holm Sidak method). No recovery of OD was
detected in SAL+RS animals (n = 5; C/I VEP ratio = 0.86 ± 0.11; One-way ANOVA, post hoc Holm Sidak method). (c) Extracellular GABA
levels were significantly lower in the VC of IGF-1-treated rats (IGF-1; n = 6; 0.87 ± 0.17 μM) with respect to saline-treated (SAL; n = 5;
4.46 ± 0.17 μM) and untreated animals (Nor; n = 8, 4.62 ± 0.97μM; One-way ANOVA, F(2–16) = 7.445, P = 0.0052, post hoc Tukey test,
P < 0.05). (d) No change in glutamate (GLU) levels between IGF-1-treated (3.88 ± 0.4 μM) and control groups (SAL: 4.48 ± 0.6 μM; Nor:
3.74 ± 0.3 μM) was detected (One-way ANOVA, F(2–15) = 0.744, P = 0.491). The grey box denotes the C/I VEP ratio range in adult normal
animals. ∗Statistical significance. Error bars indicate SEM.
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Figure 2: The upregulation of IGF-1 expression in EE animals mediates the eﬀects of enriched experience on adult VC plasticity. (a) Analysis
of gene expression by RT-PCR revealed that IGF-1 and IGFbp5 expression increased in the VC of EE animals after 2 days of MD with respect
to SC animals similarly treated (n = 8 for both experimental groups; t-test; respectively, P = 0.034 and P = 0.030). In contrast, no
modifications of either IGF1-R (t-test; P = 0.523) or IGFbp3 (t-test; P = 0.324) expression were detected. (b) The expression of IGF-1,
IGF-1R, IGFbp5, and IGFbp3 in the VC was not diﬀerent between EE animals monocularly deprived for 7 days and SC rats similarly treated.
(c) JB1 infusion prevented the OD shift induced by MD in EE animals: no diﬀerence in C/I VEP ratio between normal animals (Nor+MD;
n = 5, 2.67 ± 0.15) and EE rats treated with JB1 subjected to MD detected (EE+JB1; n = 6; 2.37 ± 0.09; One-way ANOVA, post hoc Holm
Sidak method), while monocularly deprived EE animals (EE+MD; n = 6; 0.99 ± 0.07) and EE rats treated with vehicle (EE+Veh; n = 5;
1.08 ± 0.05) showed an OD shift in favor of the open eye (One-way ANOVA, F(5–27) = 46.48, P < 0.0001, post hoc Holm Sidak method). (d)
Coupling enriched experience with IGF-1 treatment (EE+IGF1 rats) did not further enhance the OD shift induced by MD in EE animals:
the C/I VEP ratio measured in EE+IGF1 rats (n = 5; 1.08 ± 0.07) was completely comparable to that reported for EE animals (EE+MD),
while it diﬀered from that recorded in Nor+MD animals (One-way ANOVA F(5–27) = 46.48, P < 0.0001, post hoc Holm Sidak method). The
grey box denotes the C/I VEP ratio range in adult normal animals. ∗Statistical significance. NS: Not significant. Error bars indicate SEM.
P = 0.0001, post hoc Tukey’s test, P < 0.05) in adult
animals exposed to EE (EE+MD; C/I VEP ratio 0.99 ± 0.07,
n = 6) but not in EE rats intracortically infused with JB1
(EE+JB1; C/I VEP ratio 2.37 ± 0.09, n = 6), indicating that
IGF-1 signaling is critical for the eﬀects caused by EE in
VC plasticity (Figure 2(c)). EE animals infused with vehicle
solution (EE+Veh), instead, showed a marked shift of OD
after MD.
We finally examined whether the physiological reduction
of inhibition that occurs under conditions of EE [12, 19]
occludes phenomena of plasticity caused by intracortical
IGF-1 administration. Interestingly, the shift of OD induced
by EE (EE+MD; C/I VEP ratio 0.99 ± 0.07) did not diﬀer
from that caused by EE+IGF-1 treatment (C/I VEP ratio
1.08 ± 0.07). These findings suggest that the reduction of
inhibition is, at least, one of the physiological mechanisms by
which IGF-1 restores plasticity in the adult VC (Figure 2(d)).
4. Discussion
Our findings demonstrate that intracortical IGF-1 treatment
eﬀectively reinstates neural plasticity in the adult visual
system, as indicated by the enhanced susceptibility of VC
neurons in response to MD in adult life. We provide
evidence that OD plasticity in IGF-1 animals occurs through
a juvenile-like mechanism: the OD shift observed in IGF1-
treated animals, indeed, was entirely due to a marked
reduction in the deprived eye response, an event detected
in the developing VC. Even if a link between brain plasticity
and IGF-1 has been suggested by previous findings showing
that IGF-1 increases hippocampal neurogenesis [22] and
mediates the enhancement of synaptic plasticity induced by
physical activity in the adult brain [21–24], this is the first
time that the IGF-1 eﬀects have been studied using the highly
reliable paradigm of OD plasticity.
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Figure 3: The process of plasticity reactivation induced by EE is associated with signal transduction pathways that involve the activation
of long-distance neuromodulatory systems and IGF-1 signaling. We propose a model in which the interplay between 5-HT and IGF-1
transmission, in parallel or in series, shifts the inhibitory/excitatory balance in favour of excitation thus activating intracellular mechanisms
that eventually promote epigenetic modifications of chromatin structure that, in turn, allow for the expression of plasticity genes in adult life.
A pharmacological reduction of inhibitory transmission could promote Bdnf expression and activate physiological mechanisms that may
drive the degradation of extracellular matrix (ECM) components that are inhibitory for plasticity. 5-HT and IGF-1 signaling, respectively,
may also directly activate Bdnf expression or enhance the ECM remodeling. Bdnf-trkB signaling might upregulate additional gene expression
patterns associated with functional modifications in the VC. This could also alter the balance of intracortical inhibition and excitation.
Degradation of ECM components may modify the inhibition/excitation ratio in the visual system. The interaction between BDNF-trkB
signaling and ECM reorganization has yet to be explored. Continuous arrows represent established interactions between molecular and
cellular processes mentioned (boxes). Dashed lines represent interactions that remain to be ascertained.
The possibility to enhance plasticity in the adult nervous
system through IGF-1 infusion may be used to promote the
recovery of sensory functions after long-term deprivation.
Accordingly, we found that exogenous IGF-1 administration
is eﬀective in the treatment of amblyopia, a pathological
condition that lacks of a suitable treatment in adulthood.
Recent studies indicate that a great number of exper-
imental strategies promoting juvenile-like plasticity in the
adult brain cause a shift of the intracortical excitatory-
inhibitory balance [9–15, 19]. Consistently, the eﬀects caused
by IGF-1 in VC plasticity were accompanied by a decrease
of extracellular GABA levels. This suggests that a down-
regulation of the inhibitory tone may be, at least, one of
the mechanisms underlying the IGF-1-induced reactivation
of plasticity. Since IGF-1 enhances neuronal glucose uptake
[32], an increase of glucose metabolism may also contribute
to the IGF-1-induced process of plasticity reactivation. In
addition, IGF-1 may act as a subset of neurotrophic factors.
IGF-1 exogenous administration in parallel to MD during
the CP, indeed, recalls the eﬀects caused by the neurotrophins
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NGF [33] and NT-4 [34] in the developing visual system.
In this context, it is intriguing that anti-NGF antibodies, a
treatment previously shown to influence VC plasticity [33]
and to prolong the CP for plasticity in the visual system [35],
determine a major remodeling of the inhibitory-excitatory
equilibrium in the hippocampus of 6 months old anti-NGF
AD11 transgenic mice with a shift of GABA activity from
hyperpolarizing to depolarizing, due to a downregulation of
the KCC2 chloride transporter [36].
We observed that the reinstatement of plasticity caused
by EE was paralleled by a transient enhancement of IGF-
1 expression and that antagonizing IGF-1 signaling in EE
animals counteracted the process of plasticity reactivation.
Previous studies have demonstrated that the restoration
of plasticity is a multifactorial event that comprises the
action of diﬀerent cellular and molecular mechanisms,
working in parallel or in series, the sum of which results in
the activation of intracellular signal transduction pathways
regulating the expression of plasticity genes in the adult brain
[15, 37, 38], reviewed in [17, 20, 39]. The observation that
serotonin (5-HT) triggers a transient epigenetic mechanism
that reinstates OD plasticity in adulthood [15] and mediates
the plastic outcome of EE in the adult visual system [12] may
suggest that 5-HT sets in motion physiological mechanisms
underlying these plastic phenomena. However, our present
data brings IGF-1 as an additional player into this context. A
role for a combined action of 5-HT and IGF-1 signaling as
mediators of adult plasticity may be exemplified by a model
in which the 5-HT transmission increases IGF-1 expression,
which in turn could be, at least, one of the mechanisms
by which the reduction of local GABAergic inhibition
and enhancement of BDNF levels are accomplished under
EE conditions (Figure 3). Consistently, a pharmacological
increase of 5-HT transmission promotes IGF-1 expression
in diﬀerent areas of the adult brain [40, 41], whereas IGF-
1 signaling controls BDNF expression [42]. This is also in
line with the observation that EE upregulates IGF-1 signaling
in the adult rat hippocampus and sensory-motor cortex
[43].
Another possibility is that IGF-1 enhances 5-HT trans-
mission, setting in motion downstream mechanisms that
restore plasticity in adult life: hippocampal IGF-1 adminis-
tration, for instance, has been reported to initiate a long-
lasting cascade of neurochemical eﬀects involving increased
serotonin levels [44]. We cannot rule out that serotonin-
ergic transmission and IGF-1 signaling act as independent
pathways converging, in parallel, on inhibitory transmission
and BDNF signaling. Because the largest source of IGF-1
in the adult brain comes from the periphery [21–24], our
findings do not exclude the possibility that circulating IGF-1
levels may also contribute to the eﬀects caused by EE in VC
plasticity.
It is also worth mentioning that IGFbp5 expression
increased in the VC of EE animals after 2 days of MD. This
is consistent with previous findings showing that MD up
regulates IGFbp5 during the CP at the level of mRNA and
protein [25] and provides further support for an increased
bioavailability of local IGF-1 in the visual system of adult
animals after brief exposure to EE conditions [45]. Moreover,
there is evidence that IGFbp5 increases the conversion of
plasminogen into the proteolytic enzyme plasmin [46],
which suggests that the associated cleavage of extracellular
matrix proteins is likely to contribute to the plastic outcome
of EE in the adult. The process of plasticity reactivation
caused by EE, indeed, is associated to a reduction of extracel-
lular matrix molecules that are repressive for plasticity [19].
In line with this, a pharmacological removal of extracellular
matrix components restores VC plasticity in adulthood
[47, 48].
5. Conclusion
We found that IGF-1 is a molecular factor that reinstates
juvenile-like plasticity in adult VC circuitries and that this
plastic phenomenon is likely to be mediated by a reduction
of inhibitory transmission. Moreover, IGF-1 emerges as a
critical player in the process of plasticity reactivation caused
by EE in adulthood.
Given the eﬀectiveness of IGF-1 in restoring plasticity in
the adult VC, one may speculate that the beneficial eﬀects
exerted by this treatment could be exploited for clinical
application. Since deterioration in functional plasticity con-
tributes to the pathogenesis of several brain diseases, IGF-
1 arises as a therapeutic strategy to delay the progression
and/or to ameliorate the symptoms of neurodegenerative
disorders such as Alzheimer’s disease. This notion is sup-
ported by the recent observation that exogenous administra-
tion of IGF-2 promotes memory consolidation and retention
in rodents [49].
Human studies have shown a positive correlation
between IGF-1 and mental abilities [21, 50–54], and IGF-
1 has been employed for the treatment of diabetes [55,
56], growth failure [57, 58], and motor neuronal disorders
[59, 60]. Together with our finding that IGF-1 promotes
plasticity in the adult nervous system, these observations
suggest that systemic IGF-1 delivery could be used to enhance
plasticity as a strategy for brain repair in adult life. This may
be of relevance in neurological disorders in which synaptic
plasticity is compromised because of excessive intracortical
inhibition [61–63].
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